Medidata, a Dassault Systèmes company, has announced that Allucent, a contract research organisation (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.
The agreement expands Allucent’s existing utilisation of Medidata technologies. These include Rave EDC, eCOA, RTSM and Rave Imaging, in support of critical areas of development, including oncology, rare and orphan indications and cell and gene therapies.
As part of this agreement, Allucent’s team also achieved 100% Rave EDC certification, reinforcing their commitment to quality and providing their clients with best-in-class technology.
“Our partnership with Medidata allows us to continue to bring our customers the level of patient focus and insights they need and expect,” said Emily Moore, President of Biometrics at Allucent. “Making the Medidata Clinical Cloud platform available to our clients was an important step to enabling us to accelerate clinical trial development for our customers – small and mid-sized biotech companies.”
“Allucent is leveraging the power of the Medidata Clinical Cloud to solidify their position at the forefront of clinical technology,” said Janet Butler, Head of Global Sales at Medidata. “Their work with novel therapies requires agile, patient-centric solutions. We are proud to build on our eight-year collaboration to advance the Digital Transformation of life sciences and deliver clinical innovations to help reach their goals.”
